Biocon inaugurates world class manufacturing facility for its insulins portfolio

16 Sep 2015 Evaluate

Biocon, Asia’s premier biopharmaceuticals company, has inaugurated a world class facility for manufacturing new generation, patient-friendly devices for its insulins portfolio. The 100,000 square feet, state-of-the-art new devices facility set up in Bangalore will enable the company to leverage the country’s manufacturing expertise to develop world-class delivery devices for people with diabetes in India and other parts of the world. 

The pharma major has also launched Basalog One, a high-end, ready-to-use insulin glargine disposable pen for better blood sugar management for people with diabetes, manufactured in this facility. Basalog One, a long acting basal insulin glargine presented as an innovative, pre-filled pen, is the first product to roll out of this facility.

Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
 

Biocon Share Price

387.75 -6.15 (-1.56%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×